Expressions of CD147, MMP-2 and MMP-9 in Laryngeal Carcinoma and its Correlation with Poor Prognosis

Abstract

The objectives of this study are to investigate the expressions of matrix metalloproteinase inducing factor (CD147), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) in laryngeal tumor tissues and its significant correlation with tumor infiltration, metastasis and prognosis. Laryngeal tumor tissue from 48 laryngeal cancer patients with complete clinical information was collected. The laryngitis tissue from 15 patients were collected as control group. Immunohistochemical analysis for CD147, MMP-2 and MMP-9 was performed for all the tissue. The results showed the expression rates of CD147, MMP-2 and MMP-9 in laryngeal carcinoma were 87.5 %, 75.0 % and 79.2 % respectively, significantly higher than those (26.7 %, 6.7 %, and 33.3 % respectively) in the control group are (P < 0.01). High expression of CD147, MMP-2 and MMP-9 related to the clinical stages and lymphatic metastasis of laryngeal carcinoma. Univariate survival analysis showed that the 5-year survival of laryngeal carcinoma patients with low expression of CD147, MMP-2 and MMP-9was 83.3 %, 83.3 % and 90 % respectively, while the patients with high expression had 5-year survival at 25 %, 7.7 % and 18.2 % respectively (P < 0.05). Multiple regression analysis showed that high expression of MMP-9 was independently associated with poor prognosis (P < 0.05). High expression of CD147, MMP-2 and MMP-9 were related with laryngeal carcinoma invasion and metastasis. High expressions of CD147, MMP-2 and MMP-9 were all predictive factors of poor prognosis of laryngeal carcinoma.

The Biological Function and Clinical Utilization of CD147 in Human Diseases: A Review of the Current Scientific Literature

“…Patients with high CD147 expression have a poor prognosis [104], while multivariate analysis revealed that the expression of CD147 is an independent prognostic factor for patients with NSCLC [81,176]. The five-year survival rate in NSCLC cases with low CD147 expression is higher than that in cases with high expression [176], and CD147 may therefore represent a useful biomarker for prognostic evaluation.…”

CD47 is a Potential Target for the Treatment of Laryngeal Squamous Cell Carcinoma

“…Cell-surface molecules preferentially expressed on LSCC compared to their normal counterparts are potential candidates of biomarker. Thus far, several molecules, including CD34, CD44, CD105, CD133 and CD147 [6][7][8][9], have been identified as favorable markers in the prediction of LSCC. In terms of the fact that it may be insufficient to predict LSCC with only single marker, more efficient ones need to be explored [5].…”

Effect of TNFRSF6B neutralization antibody on cell growth suppression and apoptosis induction in glioma cells

“…To explore the possible molecular mechanism of the contribution of anti-TNFRSF6B antibody in glioma cells, we performed western blot to determine the influence of anti-TNFRSF6B antibody on MMP-2, ERK1/2 and AKT. MMP-2 is a proteolytic enzyme that can degrade extracellular matrix components and plays an important role in tumorigenesis, invasion and metastasis of cancers [17][18][19][20][21][22][23][24] and it has been reported that in esophageal cancer tissues, TNFRSF6B expression is positively correlated to MMP-2 [19]. The activation of ERK and AKT pathways also represent the ability of survival, proliferation and apoptosis in cancers.…”